{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:37:45Z","timestamp":1771529865217,"version":"3.50.1"},"reference-count":9,"publisher":"FapUNIFESP (SciELO)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:p>Summary  Objective: The pathogenesis of recurrent priapism is currently being investigated based on the regulation of the phosphodiesterase 5 (PDE5) enzyme. We explored the daily use of PDE5 inhibitors to treat and prevent priapism recurrences.  Method: We administered PDE5 inhibitors using a long-term therapeutic regimen in seven men with recurrent priapism, with a mean age of 29.2 years (range 21 to 35 years). Six men (85.7%) had idiopathic priapism recurrences and one man (24.3%) had sickle cell disease-associated priapism recurrences. Tadalafil 5 mg was administered daily. The mean follow-up was 6.6 months (range 3 to 12 months).  Results: Daily long-term oral PDE5 inhibitor therapy alleviated priapism recurrences in all patients. Five (71.4%) had no episodes of priapism and two (28.6%) referred decrease in their episodes of priapism. All patients referred improvement in erectile function.  Conclusion: These findings suggest the hypothesis that PDE5 dysregulation exerts a pathogenic role for both sickle cell disease-associated priapism and for idiopathic priapism, and that it offers a molecular target for the therapeutic management of priapism. These preliminary observations suggest that continuous long-term oral PDE5 inhibitor therapy may treat and prevent recurrent priapism.<\/jats:p>","DOI":"10.1590\/1806-9282.63.08.689","type":"journal-article","created":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T19:30:22Z","timestamp":1506799822000},"page":"689-692","source":"Crossref","is-referenced-by-count":12,"title":["Daily use of phosphodiesterase type 5 inhibitors as prevention for recurrent priapism"],"prefix":"10.1590","volume":"63","author":[{"given":"Archimedes","family":"Nardozza Junior","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Rodrigues","family":"Cabrini","sequence":"additional","affiliation":[{"name":"Unifesp,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ucl.2007.08.006","article-title":"Priapism: current principles and practice","volume":"34","author":"Burnett AL","year":"2007","journal-title":"Urol Clin North Am"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.urology.2005.11.045","article-title":"Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism","volume":"67","author":"Burnett AL","year":"2006","journal-title":"Urology"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/01.ju.0000087608.07371.ca","article-title":"American Urological Association guideline on the management of priapism","volume":"170","author":"Montague DK","year":"2003","journal-title":"J Urol"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.juro.2009.06.040","article-title":"Ketoconazole and prednisone to prevent recurrent ischemic priapism","volume":"182","author":"Abern MR","year":"2009","journal-title":"J Urol"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/j.1743-6109.2009.01337.x","article-title":"Increased cavernosal relaxations in sickle cell mice priapism are associated with alterations in NO-cGMP signaling pathway","volume":"6","author":"Claudino MA","year":"2009","journal-title":"J Sex Med"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1073\/pnas.0407183102","article-title":"Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism","volume":"102","author":"Champion HC","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1743-6109.2006.00333.x","article-title":"Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism","volume":"3","author":"Burnett AL","year":"2006","journal-title":"J Sex Med"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0022-5347(17)44746-X","article-title":"Priapism: a re?ned approach to diagnosis and treatment","volume":"136","author":"Lue TF","year":"1986","journal-title":"J Urol"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1743-6109.2007.00631.x","article-title":"Glucose-6-phosphate dehydrogenase de?ciency: an etiology for idiopathic priapism?","volume":"5","author":"Burnett AL","year":"2008","journal-title":"J Sex Med"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v63n8\/0104-4230-ramb-63-08-0689.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T18:03:17Z","timestamp":1508954597000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302017000800689&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0104-42302017000800689"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.63.08.689","relation":{},"ISSN":["0104-4230"],"issn-type":[{"value":"0104-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}